We are AAVnerGene, a pioneering company in the US focusing on adeno-associated virus (AAV) as a platform for gene therapy. Established in 2019, our goal is to increase the accessibility of gene therapy by addressing the bottleneck challenges that hinder its broader adoption because of issues with cost, production scaling, and systemic side effects.
Our innovations include mini-pHelper and AAVone, production systems that address challenges in production scalability by increasing yields by up to 400%. Our AAV libraries include over 1000 known serotypes, in addition to production of custom libraries to target specific cells and tissues, allowing us to deliver effective doses while minimizing systemic side effects.
Our dedicated team brings together a wealth of knowledge, experience, and innovation. By continually pushing boundaries and exploring new avenues, we're dedicated to reshaping the future of healthcare. Join us in our quest to make gene therapy a reality for all.